Paola Torelli
Overview
Explore the profile of Paola Torelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbanti P, Aurilia C, Torelli P, Egeo G, dOnofrio F, Finocchi C, et al.
J Neurol
. 2025 Jan;
272(2):170.
PMID: 39862304
Objectives: To determine whether extending anti-CGRP mAb treatment beyond 3 years influences migraine course, we analyzed migraine frequency during the first month of treatment discontinuation following three 12-month treatment cycles...
2.
Castaldo M, Arendt-Nielsen L, Ponzano M, Bovis F, Torelli P, Finocchi C, et al.
Eur J Pain
. 2025 Jan;
29(2):e4787.
PMID: 39836392
Aim: Identify values that could predict the presence of increased pressure-pain sensitivity independent of the migraine cycle through a single assessment. Methods: This was a secondary analysis of a previous...
3.
Guidotti S, Torelli P, Ambiveri G, Fiduccia A, Castaldo M, Pruneti C
Neurol Sci
. 2024 Aug;
46(1):313-323.
PMID: 39187673
Objective: The literature on clinical psychophysiology highlights the possibility of using Heart Rate Variability (HRV) as an index of psychophysical balance and resilience to stress. This study investigates the differences...
4.
Barbanti P, Egeo G, Proietti S, dOnofrio F, Aurilia C, Finocchi C, et al.
Neurol Ther
. 2024 Aug;
13(5):1505-1506.
PMID: 39106033
No abstract available.
5.
Caronna E, Gallardo V, Egeo G, Vazquez M, Castellanos C, Membrilla J, et al.
J Neurol Neurosurg Psychiatry
. 2024 May;
95(10):927-937.
PMID: 38777579
Background: Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike and many countries have reimbursement policies, which hinder treatments to those...
6.
Barbanti P, Aurilia C, Egeo G, Proietti S, dOnofrio F, Torelli P, et al.
J Neurol
. 2024 Apr;
271(5):2444-2445.
PMID: 38564057
No abstract available.
7.
Barbanti P, Egeo G, Proietti S, dOnofrio F, Aurilia C, Finocchi C, et al.
Neurol Ther
. 2024 Mar;
13(3):611-624.
PMID: 38451463
Introduction: Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and < 2 medication clusters in a randomized controlled trial (RCT). We aimed...
8.
Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, dOnofrio F, et al.
J Neurol
. 2024 Feb;
271(5):2605-2614.
PMID: 38342785
Objectives: While a single 12-month treatment cycle (TrC) with anti-CGRP mAbs is not disease-modifying for most patients, there is limited understanding of the effects of multiple TrCs on migraine course....
9.
Barbanti P, Aurilia C, Egeo G, Proietti S, dOnofrio F, Torelli P, et al.
J Neurol
. 2024 Jan;
271(5):2434-2443.
PMID: 38231271
Objective: Nearly 60% of migraine patients treated with monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway experience a ≥ 50% reduction in monthly migraine days (MMD) at 12 ...
10.
Di Antonio S, Arendt-Nielsen L, Ponzano M, Bovis F, Torelli P, Elisa P, et al.
Neurol Sci
. 2023 Oct;
45(3):1185-1200.
PMID: 37833507
Aims: Investigate if different clinical and psychophysical bedside tools can differentiate between district migraine phenotypes in ictal/perictal (cohort 1) and interictal (cohort 2) phases. Method: This observational study included two...